Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Agilent Technologies, Inc. stock logo
A
Agilent Technologies
$138.23
+0.6%
$117.41
$108.35
$160.27
$38.81B1.262.61 million shs2.13 million shs
Charles River Laboratories International, Inc. stock logo
CRL
Charles River Laboratories International
$185.65
+3.2%
$171.05
$140.78
$228.88
$8.66B1.46937,128 shs736,749 shs
Icon Plc stock logo
ICLR
Icon
$152.96
+6.3%
$116.52
$66.57
$211.00
$11.62B1.261.04 million shs1.69 million shs
Bio-Techne Corp stock logo
TECH
Bio-Techne
$53.18
+4.6%
$52.02
$43.19
$72.16
$7.96B1.372.92 million shs4.20 million shs
10 Stocks Powering The Next AI Boom  Cover

The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation.

Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Agilent Technologies, Inc. stock logo
A
Agilent Technologies
+2.20%+19.16%+20.46%+16.85%+22.39%
Charles River Laboratories International, Inc. stock logo
CRL
Charles River Laboratories International
+3.17%+9.44%+8.55%-0.79%+29.83%
Icon Plc stock logo
ICLR
Icon
+4.79%+21.67%+27.71%+30.31%+7.75%
Bio-Techne Corp stock logo
TECH
Bio-Techne
+2.17%+5.74%-7.58%-9.02%+4.24%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Agilent Technologies, Inc. stock logo
A
Agilent Technologies
$138.23
+0.6%
$117.41
$108.35
$160.27
$38.81B1.262.61 million shs2.13 million shs
Charles River Laboratories International, Inc. stock logo
CRL
Charles River Laboratories International
$185.65
+3.2%
$171.05
$140.78
$228.88
$8.66B1.46937,128 shs736,749 shs
Icon Plc stock logo
ICLR
Icon
$152.96
+6.3%
$116.52
$66.57
$211.00
$11.62B1.261.04 million shs1.69 million shs
Bio-Techne Corp stock logo
TECH
Bio-Techne
$53.18
+4.6%
$52.02
$43.19
$72.16
$7.96B1.372.92 million shs4.20 million shs
10 Stocks Powering The Next AI Boom  Cover

The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation.

Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Agilent Technologies, Inc. stock logo
A
Agilent Technologies
+2.20%+19.16%+20.46%+16.85%+22.39%
Charles River Laboratories International, Inc. stock logo
CRL
Charles River Laboratories International
+3.17%+9.44%+8.55%-0.79%+29.83%
Icon Plc stock logo
ICLR
Icon
+4.79%+21.67%+27.71%+30.31%+7.75%
Bio-Techne Corp stock logo
TECH
Bio-Techne
+2.17%+5.74%-7.58%-9.02%+4.24%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Agilent Technologies, Inc. stock logo
A
Agilent Technologies
2.94
Moderate Buy$161.7116.99% Upside
Charles River Laboratories International, Inc. stock logo
CRL
Charles River Laboratories International
2.63
Moderate Buy$208.5012.31% Upside
Icon Plc stock logo
ICLR
Icon
2.33
Hold$156.442.27% Upside
Bio-Techne Corp stock logo
TECH
Bio-Techne
2.79
Moderate Buy$65.9223.96% Upside

Current Analyst Ratings Breakdown

Latest CRL, ICLR, TECH, and A Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
6/3/2026
Agilent Technologies, Inc. stock logo
A
Agilent Technologies
Lower Price TargetBuy$180.00 ➝ $165.00
6/2/2026
Agilent Technologies, Inc. stock logo
A
Agilent Technologies
UpgradeHold (C-)Hold (C)
6/2/2026
Agilent Technologies, Inc. stock logo
A
Agilent Technologies
Reiterated RatingHold
6/1/2026
Icon Plc stock logo
ICLR
Icon
Set Price Target$164.00
6/1/2026
Icon Plc stock logo
ICLR
Icon
Boost Price TargetBuy$120.00 ➝ $164.00
6/1/2026
Icon Plc stock logo
ICLR
Icon
Reiterated RatingOutperform
5/29/2026
Charles River Laboratories International, Inc. stock logo
CRL
Charles River Laboratories International
UpgradeSell (E+)Sell (D-)
5/29/2026
Icon Plc stock logo
ICLR
Icon
DowngradeSell (D+)Sell (D)
5/29/2026
Icon Plc stock logo
ICLR
Icon
Boost Price TargetHold$139.00 ➝ $159.00
5/29/2026
Icon Plc stock logo
ICLR
Icon
Reiterated RatingBuy$165.00
5/29/2026
Icon Plc stock logo
ICLR
Icon
Boost Price TargetSector Perform$123.00 ➝ $126.00
(Data available from 6/4/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Agilent Technologies, Inc. stock logo
A
Agilent Technologies
$6.95B5.62$6.67 per share20.72$25.22 per share5.48
Charles River Laboratories International, Inc. stock logo
CRL
Charles River Laboratories International
$4.02B2.23$22.67 per share8.19$64.39 per share2.88
Icon Plc stock logo
ICLR
Icon
$8.25B1.50$16.98 per share9.01$113.84 per share1.34
Bio-Techne Corp stock logo
TECH
Bio-Techne
$1.22B6.83$2.56 per share20.80$12.24 per share4.34
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Agilent Technologies, Inc. stock logo
A
Agilent Technologies
$1.30B$4.9827.7621.042.4519.55%24.33%12.99%N/A
Charles River Laboratories International, Inc. stock logo
CRL
Charles River Laboratories International
-$144.34M-$3.76N/A15.412.06-4.59%15.36%6.61%8/5/2026 (Estimated)
Icon Plc stock logo
ICLR
Icon
$229.34M$6.1624.8311.694.945.98%9.50%5.40%7/22/2026 (Estimated)
Bio-Techne Corp stock logo
TECH
Bio-Techne
$73.40M$0.6977.0729.063.969.05%13.57%10.66%8/5/2026 (Estimated)

Latest CRL, ICLR, TECH, and A Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
6/3/2026Q1 2026
Icon Plc stock logo
ICLR
Icon
$3.20$2.52-$0.68$1.93$1.99 billion$2.11 billion
5/27/2026Q2 2026
Agilent Technologies, Inc. stock logo
A
Agilent Technologies
$1.41$1.49+$0.08$1.20$1.80 billion$1.84 billion
5/7/2026Q1 2026
Charles River Laboratories International, Inc. stock logo
CRL
Charles River Laboratories International
$1.96$2.06+$0.10-$0.30$977.46 million$995.83 million
5/6/2026Q3 2026
Bio-Techne Corp stock logo
TECH
Bio-Techne
$0.55$0.53-$0.02$0.32$316.11 million$311.42 million
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Agilent Technologies, Inc. stock logo
A
Agilent Technologies
$1.020.74%+6.58%20.48%9 Years
Charles River Laboratories International, Inc. stock logo
CRL
Charles River Laboratories International
N/AN/AN/AN/AN/A
Icon Plc stock logo
ICLR
Icon
N/AN/AN/AN/AN/A
Bio-Techne Corp stock logo
TECH
Bio-Techne
$0.320.60%N/A46.38%N/A

Latest CRL, ICLR, TECH, and A Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
5/20/2026
Agilent Technologies, Inc. stock logo
A
Agilent Technologies
quarterly$0.25500.9%6/30/20266/30/20267/22/2026
5/6/2026
Bio-Techne Corp stock logo
TECH
Bio-Techne
quarterly$0.080.72%5/18/20265/18/20265/29/2026
(Data available from 1/1/2013 forward)
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Agilent Technologies, Inc. stock logo
A
Agilent Technologies
0.43
2.10
1.62
Charles River Laboratories International, Inc. stock logo
CRL
Charles River Laboratories International
0.90
1.36
1.03
Icon Plc stock logo
ICLR
Icon
0.31
1.10
1.10
Bio-Techne Corp stock logo
TECH
Bio-Techne
0.10
4.49
3.18

Institutional Ownership

CompanyInstitutional Ownership
Agilent Technologies, Inc. stock logo
A
Agilent Technologies
N/A
Charles River Laboratories International, Inc. stock logo
CRL
Charles River Laboratories International
98.91%
Icon Plc stock logo
ICLR
Icon
95.61%
Bio-Techne Corp stock logo
TECH
Bio-Techne
98.95%

Insider Ownership

CompanyInsider Ownership
Agilent Technologies, Inc. stock logo
A
Agilent Technologies
N/A
Charles River Laboratories International, Inc. stock logo
CRL
Charles River Laboratories International
1.30%
Icon Plc stock logo
ICLR
Icon
44.00%
Bio-Techne Corp stock logo
TECH
Bio-Techne
1.30%
CompanyEmployeesShares OutstandingFree FloatOptionable
Agilent Technologies, Inc. stock logo
A
Agilent Technologies
18,100282.43 millionN/AOptionable
Charles River Laboratories International, Inc. stock logo
CRL
Charles River Laboratories International
19,70048.17 million47.54 millionOptionable
Icon Plc stock logo
ICLR
Icon
41,90080.76 million45.22 millionOptionable
Bio-Techne Corp stock logo
TECH
Bio-Techne
3,100156.57 million154.53 millionOptionable

Recent News About These Companies

CMB.TECH NV (CMBT) Q1 2026 Earnings Call Transcript
Bio-Techne Corp TE1
Bio-Techne (TECH) Q3 2026 Earnings Transcript
Bio-Techne Q3 Earnings Call Highlights

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Agilent Technologies stock logo

Agilent Technologies NYSE:A

$138.23 +0.83 (+0.61%)
Closing price 03:59 PM Eastern
Extended Trading
$138.46 +0.23 (+0.16%)
As of 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Agilent Technologies, Inc. provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. The company operates in three segments: Life Sciences and Applied Markets, Diagnostics and Genomics, and Agilent CrossLab. The Life Sciences and Applied Markets segment offers liquid chromatography systems and components; liquid chromatography mass spectrometry systems; gas chromatography systems and components; gas chromatography mass spectrometry systems; inductively coupled plasma mass spectrometry instruments; atomic absorption instruments; microwave plasma-atomic emission spectrometry instruments; inductively coupled plasma optical emission spectrometry instruments; raman spectroscopy; cell analysis plate based assays; flow cytometer; real-time cell analyzer; cell imaging systems; microplate reader; laboratory software; information management and analytics; laboratory automation and robotic systems; dissolution testing; and vacuum pumps, and measurement technologies. The Diagnostics and Genomics segment focuses on genomics, nucleic acid contract manufacturing and research and development, pathology, companion diagnostics, reagent partnership, and biomolecular analysis businesses. The Agilent CrossLab segment provides GC and LC columns, sample preparation products, custom chemistries, and laboratory instrument supplies; and offers services portfolio, including repairs, parts, maintenance, installations, training, compliance support, software as a service, asset management, and consulting services. The company markets its products through direct sales, distributors, resellers, manufacturer's representatives, and electronic commerce. Agilent Technologies, Inc. was incorporated in 1999 and is headquartered in Santa Clara, California.

Charles River Laboratories International stock logo

Charles River Laboratories International NYSE:CRL

$185.65 +5.78 (+3.21%)
Closing price 03:59 PM Eastern
Extended Trading
$185.95 +0.30 (+0.16%)
As of 07:17 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Charles River Laboratories International, Inc. provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing). The RMS segment produces and sells rodents, and purpose-bred rats and mice for use by researchers. This segment also provides a range of services to assist its clients in supporting the use of research models in research and screening pre-clinical drug candidates, including research models, genetically engineered models and services, insourcing solutions, and research animal diagnostic services. The DSA segment offers early and in vivo discovery services for the identification and validation of novel targets, chemical compounds, and antibodies through delivery of preclinical drug and therapeutic candidates ready for safety assessment; and safety assessment services, such as toxicology, pathology, safety pharmacology, bioanalysis, drug metabolism, and pharmacokinetics services. The Manufacturing segment provides in vitro methods for conventional and rapid quality control testing of sterile and non-sterile pharmaceuticals and consumer products. This segment also offers specialized testing of biologics that are outsourced by pharmaceutical and biotechnology companies. It also provides contract vivarium operation services to biopharmaceutical clients. The company was founded in 1947 and is headquartered in Wilmington, Massachusetts.

Icon stock logo

Icon NASDAQ:ICLR

$152.96 +9.06 (+6.30%)
Closing price 03:59 PM Eastern
Extended Trading
$152.78 -0.18 (-0.12%)
As of 05:55 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

ICON Public Limited Company, a clinical research organization, provides outsourced development and commercialization services in Ireland, rest of Europe, the United States, and internationally. The company specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies. It also offers clinical development services, including all phases of development, peri and post approval, data solutions, and site and patient access services; clinical trial management, consulting, and contract staffing services; and commercial services comprising clinical development strategy, planning and trial design, full study execution, and post-market commercialization. In addition, the company provides laboratory services, including bionanalytical, biomarker, vaccine, good manufacturing practice, and central laboratory services, as well as full-service and functional service partnerships to customers. Further, it offers adaptive trials, cardiac safety solutions, clinical and scientific operations, consulting and advisory, commercial positioning, decentralized and hybrid clinical trials, early clinical, laboratories, language services, medical imaging, real world intelligence, site and patient, and strategic solutions. The company serves pharmaceutical, biotechnology, and medical device industries, as well as government and public health organizations. ICON Public Limited Company was incorporated in 1990 and is headquartered in Dublin, Ireland.

Bio-Techne stock logo

Bio-Techne NASDAQ:TECH

$53.18 +2.33 (+4.58%)
Closing price 04:00 PM Eastern
Extended Trading
$53.06 -0.12 (-0.22%)
As of 07:46 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research and clinical diagnostic markets in the United States, the United Kingdom, rest of Europe, Middle East, and Africa, Greater China, rest of Asia-Pacific, and internationally. The company operates through two segments, Protein Sciences, and Diagnostics and Genomics. The Protein Sciences segment develops and manufactures biological reagents used in various aspects of life science research, diagnostics, and cell and gene therapy, such as cytokines and growth factors, antibodies, small molecules, tissue culture sera, and cell selection technologies. This segment also offers proteomic analytical tools for automated western blot and multiplexed ELISA workflow consists of manual and automated protein analysis instruments and immunoassays for use in quantifying proteins in various biological fluids. The Diagnostics and Genomics segment develops and manufactures diagnostic products, including controls, calibrators, and diagnostic assays for regulated diagnostics market, exosome-based molecular diagnostic assays, advanced tissue-based in-situ hybridization assays for spatial genomic and tissue biopsy analysis, and genetic and oncology kits for research and clinical applications; and sells products for genetic carrier screening, oncology diagnostics, molecular controls, and research, as well as instruments and process control products for hematology, blood chemistry and gases, and coagulation controls and reagents used in various diagnostic applications. The company was formerly known as Techne Corporation and changed its name to Bio-Techne Corporation in November 2014. Bio-Techne Corporation was incorporated in 1976 and is headquartered in Minneapolis, Minnesota.